Endo Calc vs ReviewX by Patient10x Kullanım & İstatistikleri

Endo Calc is an app developed for the practicing endocrinologist by an endocrinologist. Many routine tasks that require complex calculations can be done using Endo Tools in a few clicks! Features include: 1) Convert HbA1c to average blood glucose and fructosamine. 2) Convert steroids. 3) Thyroid nodule volume calculator 4) Thyroid cancer staging 5) Thyroxine dose calculator 6) Calcium corrected for albumin 7) Fractional excretion of calcium for familial benign hypocalcuric hypercalcemia 8) NAFLD fibrosis score and several other calculators. The information on this App is not a substitute for professional medical advice, diagnosis, or treatment. All content, including text, graphics, images, and information, contained on or available through this App is for general information purposes only. This app is intended for educational purposes only and is not intended to diagnose, treat or cure any disease based on the sole output of the app. Seek a doctor’s advice in addition to using this app and before making any medical decisions.
  • Apple App Store
  • Ücretliler
  • Araçlar

Mağaza Sıralaması

- -

The ReviewX iPad app will help you dramatically improve your patient feedback and online reputation by capturing the feedback from every patient that walks through your doors. Terms of Use (EULA): https://www.apple.com/legal/internet-services/itunes/dev/stdeula/ Privacy Policy: https://www.patient10x.com/privacy-policy
  • Apple App Store
  • BOŞTA
  • Araçlar

Mağaza Sıralaması

- -

Endo Calc ile ReviewX by Patient10x için sıralama karşılaştırması

Son 28 gündeki Endo Calc sıralama trendini ReviewX by Patient10xile karşılaştırın

Rank

Mevcut veri yok

Endo Calc vs. ReviewX by Patient10x ülke karşılaştırmasına göre sıralama

Son 28 gündeki Endo Calc sıralama trendini ReviewX by Patient10xile karşılaştırın

Gösterilecek bilgi yok

Ücretsiz deneme sürümümüzü kullanarak istediğiniz siteyle karşılaştırın

Başlayın
Endo Calc VS.
ReviewX by Patient10x

Aralık 19, 2024